A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
Purpose: We report a case where tacrolimus eye drops may have alleviated immune checkpoint inhibitor (ICI)-related conjunctivitis attributed to nivolumab. Observations: A 61-year-old female complained of conjunctival hyperemia and eyelid swelling in both eyes. The patient was previously undergoing t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993625000210 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861193763192832 |
|---|---|
| author | Ayaka Kawaguchi Hayato Tanaka Hitoshi Tabuchi Kei Nakai Atsuki Fukushima |
| author_facet | Ayaka Kawaguchi Hayato Tanaka Hitoshi Tabuchi Kei Nakai Atsuki Fukushima |
| author_sort | Ayaka Kawaguchi |
| collection | DOAJ |
| description | Purpose: We report a case where tacrolimus eye drops may have alleviated immune checkpoint inhibitor (ICI)-related conjunctivitis attributed to nivolumab. Observations: A 61-year-old female complained of conjunctival hyperemia and eyelid swelling in both eyes. The patient was previously undergoing treatment for gastric cancer with nivolumab, with the final dose administered one week before the first ophthalmology visit. Initially, the patient was diagnosed with allergic conjunctivitis, managed with 0.1 % fluorometholone eye drops, 4 times daily in both eyes, but the symptoms did not improve despite 27 weeks of treatment, ICI-related conjunctivitis was considered, and the patient was prescribed with, 0.1 % tacrolimus eye drops twice daily in both eyes. One week later, there was a remarkable improvement in the conjunctival symptoms. Three months after, the conjunctival hyperemia reduced and swelling disappeared in both eyes, and, the frequency of instillation was reduced to once daily. The condition remains in remission with 0.1 % tacrolimus eye drops applied once daily in both eyes. Conclusions: Tacrolimus eye drops may have played a role to suppress ICI-related conjunctivitis. |
| format | Article |
| id | doaj-art-8b09259e540347a3ac802ce6d41c22da |
| institution | Kabale University |
| issn | 2451-9936 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj-art-8b09259e540347a3ac802ce6d41c22da2025-02-10T04:34:38ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362025-03-0137102268A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye dropsAyaka Kawaguchi0Hayato Tanaka1Hitoshi Tabuchi2Kei Nakai3Atsuki Fukushima4Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo, JapanDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo, JapanDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo, Japan; Department of Technology and Design Thinking for Medicine, Hiroshima University Graduate School of Medicine, Hiroshima, JapanDepartment of Ophthalmology, Yodogawa Christian Hospital, Higashiyodogawa, Osaka, JapanDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo, Japan; Corresponding author. Department of Ophthalmology, Saneikai Tsukazaki Hospital, Aboshi-ku waku 68-1, Himeji, Hyogo, 671-1227, Japan.Purpose: We report a case where tacrolimus eye drops may have alleviated immune checkpoint inhibitor (ICI)-related conjunctivitis attributed to nivolumab. Observations: A 61-year-old female complained of conjunctival hyperemia and eyelid swelling in both eyes. The patient was previously undergoing treatment for gastric cancer with nivolumab, with the final dose administered one week before the first ophthalmology visit. Initially, the patient was diagnosed with allergic conjunctivitis, managed with 0.1 % fluorometholone eye drops, 4 times daily in both eyes, but the symptoms did not improve despite 27 weeks of treatment, ICI-related conjunctivitis was considered, and the patient was prescribed with, 0.1 % tacrolimus eye drops twice daily in both eyes. One week later, there was a remarkable improvement in the conjunctival symptoms. Three months after, the conjunctival hyperemia reduced and swelling disappeared in both eyes, and, the frequency of instillation was reduced to once daily. The condition remains in remission with 0.1 % tacrolimus eye drops applied once daily in both eyes. Conclusions: Tacrolimus eye drops may have played a role to suppress ICI-related conjunctivitis.http://www.sciencedirect.com/science/article/pii/S2451993625000210Tacrolimus eye dropsImmune checkpoint inhibitor-related conjunctivitisImmune-related adverse eventsnivolumab |
| spellingShingle | Ayaka Kawaguchi Hayato Tanaka Hitoshi Tabuchi Kei Nakai Atsuki Fukushima A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops American Journal of Ophthalmology Case Reports Tacrolimus eye drops Immune checkpoint inhibitor-related conjunctivitis Immune-related adverse events nivolumab |
| title | A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops |
| title_full | A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops |
| title_fullStr | A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops |
| title_full_unstemmed | A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops |
| title_short | A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops |
| title_sort | case of immune checkpoint inhibitor related conjunctivitis controlled by tacrolimus eye drops |
| topic | Tacrolimus eye drops Immune checkpoint inhibitor-related conjunctivitis Immune-related adverse events nivolumab |
| url | http://www.sciencedirect.com/science/article/pii/S2451993625000210 |
| work_keys_str_mv | AT ayakakawaguchi acaseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT hayatotanaka acaseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT hitoshitabuchi acaseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT keinakai acaseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT atsukifukushima acaseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT ayakakawaguchi caseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT hayatotanaka caseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT hitoshitabuchi caseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT keinakai caseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops AT atsukifukushima caseofimmunecheckpointinhibitorrelatedconjunctivitiscontrolledbytacrolimuseyedrops |